NMU, neuromedin U, 10874

N. diseases: 68; N. variants: 5
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0028754
Disease: Obesity
Obesity
0.250 Biomarker disease BEFREE Recently, there has been an increased focus on NMU as a promising treatment option for diabetes and obesity. 28657315 2017
CUI: C0028754
Disease: Obesity
Obesity
0.250 Biomarker disease BEFREE These results suggest that PEGylated NMU-8 has the therapeutic potential for treatment of obesity. 28400225 2017
CUI: C0028754
Disease: Obesity
Obesity
0.250 Biomarker disease RGD After 1 month of the high-fat diet, however, the obesity-resistant rats showed significantly more NMU-induced physical activity compared to the obese DIO rats. 17706946 2007
CUI: C0028754
Disease: Obesity
Obesity
0.250 GeneticVariation disease BEFREE A total of 289 Czech children and adolescents with early-onset obesity and 84 Danish obese adults were analyzed for variants in NMU. 16984985 2006
CUI: C0028754
Disease: Obesity
Obesity
0.250 Biomarker disease BEFREE Screening of neuromedin U2 receptor (NMU2R) ligands may be very useful to treat obesity for the reason that centrally administered neuromedin U affects feeding behavior, energy expenditure, and pituitary. 16111886 2005
CUI: C0028754
Disease: Obesity
Obesity
0.250 GeneticVariation disease BEFREE Studies of the neuromedin U-2 receptor gene in human obesity: evidence for the existence of two ancestral forms of the receptor. 15525579 2004
CUI: C0001925
Disease: Albuminuria
Albuminuria
0.100 GeneticVariation phenotype GWASCAT Genetic Association of Albuminuria with Cardiometabolic Disease and Blood Pressure. 30220432 2018
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.060 Biomarker group BEFREE Neuromedin U: A Small Peptide in the Big World of Cancer. 31492042 2019
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.060 AlteredExpression group BEFREE The Cancer Genome Atlas data indicated that high YAP1 and NMU expression levels were associated with poor mean and overall survival. 31575084 2019
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.060 AlteredExpression phenotype BEFREE YAP1 overexpression induced NMU expression and transcription and promoted cell motility in vitro and tumor metastasis in vivo via upregulation of epithelial-mesenchymal transition (EMT), whereas specific inhibition of NMU in cells stably expressing YAP1 had the opposite effect in vitro and in vivo. 31575084 2019
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.060 AlteredExpression phenotype BEFREE Neuromedin U (NMU), a neuropeptide isolated from porcine spinal cord and named because of its activity as a rat uterus smooth muscle contraction inducer, is emerging as a new player in the tumorigenesis and/or metastasis of many types of cancers. 31492042 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.060 Biomarker group BEFREE Our results demonstrated that CPF increases tumor incidence and reduces latency of NMU-induced mammary tumors. 30290214 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.060 AlteredExpression group BEFREE Analysis of different pancreatic cancer databases showed that Neuromedin U (NMU) expression was positively correlated with YAP1 expression in the tumor group. 31575084 2019
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.060 Biomarker phenotype BEFREE Long non-coding RNA HAND2-AS1 inhibits invasion and metastasis in endometrioid endometrial carcinoma through inactivating neuromedin U. 29107108 2018
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.060 AlteredExpression group BEFREE Overexpression of NmU also resulted in upregulation of epithelial-mesenchymal transition markers and increased IL-6 secretion which, together with aberrant metabolism, have all been associated with the cancer stem cell (CSC) phenotype. 28340506 2017
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.060 Biomarker group BEFREE Neuromedin U (NMU) has been shown driving the progression of various tumor entities, including breast cancer. 28423716 2017
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.060 AlteredExpression phenotype BEFREE The expression levels of Nmu in primary tumors with regional metastasis were higher, compared with those without metastasis. 27279246 2016
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.060 AlteredExpression group BEFREE Subsequently, the expression of Nmu was investigated using a tissue microassay to analyze the association between Nmu protein expression and Tumor Node Metastasis (TNM) status. 27279246 2016
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.060 Biomarker group BEFREE Thus, these results not only reveal the presence of previously uncharacterized heteromeric relationships among NMU receptors but also provide NMUR2S as a potential therapeutic target for the future treatment of NMU signaling-mediated cancers. 26317338 2015
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.060 Biomarker phenotype BEFREE In vivo studies revealed that NmU attenuation impaired tumor growth and metastasis. 24876102 2014
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.060 Biomarker group BEFREE In vivo studies revealed that NmU attenuation impaired tumor growth and metastasis. 24876102 2014
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.060 Biomarker group BEFREE Although NmU exerted no effects on cancer cell proliferation, it induced c-Met and a trend towards increased invasiveness as well as an increased hepatocyte growth factor (HGF)-mediated scattering. 19118941 2009
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.060 Biomarker group BEFREE In conclusion, NMU is a RhoGDI2-regulated gene that appears important for tumorigenicity, lung metastasis and cancer cachexia, and thus a promising therapeutic target in cancer. 16878152 2007
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.060 AlteredExpression phenotype LHGDN Recently, we noted an inverse correlation between tumor RhoGDI2 and Neuromedin U (NMU) expression, suggesting that NMU might be a target of the lung metastasis suppressor effect of RhoGDI2. 16878152 2007
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.060 Biomarker phenotype BEFREE Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia. 16878152 2007